Articles tagged with: Revlimid
An advisory committee of the European Medicines Agency last Thursday granted a positive opinion regarding European approval of Revlimid for the treatment of certain patients with myelodysplastic syndromes.
Specifically, the Committee for Medicinal Products for Human Use (CHMP) recommended approval for the use of Revlimid (lenalidomide) in low- or intermediate-1-risk myelodysplastic syndromes (MDS) patients who have the deletion 5q chromosomal abnormality and no other chromosomal abnormalities, are dependent on red blood cell transfusions, and for whom other treatment options have been found to be insufficient or inadequate.
The European Medicines …
Results of a small Italian Phase 2 clinical trial show that Revlimid improves important aspects of quality of life in myelodysplastic syndromes patients with a deletion in chromosome 5.
The study also found that, in a majority of the same group of patients, Revlimid (lenalidomide) improved red blood cell counts and reduced the presence of chromosomal abnormalities.
Although many of the patients in the trial experienced treatment-related side effects, the Italian researchers consider Revlimid to be well tolerated, and they believe their findings support use of the drug in patients …
Results of a small, German Phase 1 trial indicate that treatment with Vidaza followed by Revlimid may be effective in higher-risk myelodysplastic syndromes and acute myeloid leukemia patients with a deletion in chromosome 5.
Based on their findings, the researchers recommend that the combination be investigated further as first-line therapy in higher-risk myelodysplastic syndromes (MDS) patients with a deletion in chromosome 5.
Despite recent advances in the treatment of MDS, many patients eventually fail treatment. Researchers are therefore exploring innovative treatment approaches for patients who fail treatment with standard therapy.…
Results of a small retrospective study suggest that lower-risk, transfusion-dependent myelodysplastic syndromes patients with a deletion in chromosome 5 may achieve long-term transfusion independence with Revlimid, even after discontinuation of treatment.
The study authors found that patients who received Revlimid for six months after their chromosomal abnormalities disappeared had the longest transfusion-free interval.
However, they caution that Revlimid should not be discontinued in all patients who achieve transfusion independence because certain patients have a higher risk of relapse.
Based on their findings, the researchers conclude that treatment discontinuation may be …
Results from a recent Phase 1 study show that Revlimid in combination with Velcade may be effective and safe in myelodysplastic syndromes.
Specifically, 28 percent of myelodysplastic syndromes (MDS) patients responded to the combination treatment. In addition, patients receiving the highest tested dosage of Velcade (bortezomib) did not experience any dose-limiting side effects.
Based on their findings, the study investigators concluded that the combination will be tested further in patients with advanced MDS and acute myeloid leukemia (AML).
These findings were presented at the 2012 annual meeting of the American …